Vaccinare
Morbillo 2000
GIORGIO BARTOLOZZI
Direttore Scientifico, Azienda “Meyer”, Firenze
Febbraio 2000 - pagg. 119 -122
Parole chiave
Suggerite dall'AI
Classificazione MeSH
Bibliografia
1. American Academy of Pediatrics. Morbillo,
Red Book, 3° ed. italiana. Milano: CIS,
1997, pag. 356-69.
2. Bennett JV, Cutts FT, Katz SL. Edmonston- Zagreb measles vaccine: a good vaccine with an image problem. Pediatrics 1999;04: 1123.
3. Centers for Disease Control and Prevention Measles eradication: recommendation from Meeting cosponsored by the World Health Organization, the Pan American Health Organization, and CDC. MMWR 1997; 46:No RR-11.
4. Centers for Disease Control and Prevention, Measles, United States, 1997. MMWR 1998;47:273-6.
5. Centers for Disease Control and Prevention. Epidemiology of measles, United States
1998. MMWR 1999;48:749-53.
6. Conferenza permanente per i rapporti tra lo Stato, le Regioni e le Province autonome di Trento e di Bolzano – Piano Nazionale Vaccini 1999-2000. Gazzetta Ufficiale n. 176 del 29 luglio 1999, serie generale.
7. De Serres G, Joly JR, Fauvel M, et al. Passive immunity against measles during the first 8 months of life of infant born to vaccinated mothers or to mothers who sustained measles. Vaccine 1997;15:620-3.
8. Gans HA, Arvin AM, Galinus J. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA 1998;280:527-32.
9. German B, Sirota L, Barzilai A, et al. Placental transfer of maternal measles antibodies to pre-term and full-term infants. American Pediatric Society for Pediatric Research, 1-5 maggio 1998, New Orleans (839 abstract).
10. Grilli G, Cimini D, Vacca F, et al. Effetti collaterali e sieroconversione dopo la vaccinazione contro il morbillo, effettuata con ceppi vaccinali Edmonston-Zagreb e Schwarz. Notiz Ist Sup Sanità 1994;7:1-8.
11. Gruppo di lavoro ICONA - ICONA: indagine nazionale sulla copertura vaccinale infantile. Rapporti ISTISAN, ISS 98/33.
12. James JM, Burks AW, Roberson PK, Sampson HA. Safe administration of the measles vaccine to children allergic to eggs. N Engl J Med 1995;332:1262-6.
13. Markowitz L, Sepulveda J, Diaz-Ortega JL. Immunization of six-months-old infants with different doses of Edmonston-Zagreb vaccine at age 6 months. N Engl J Med 1990;322:580-7.
14. Nates SV, Cumino A, Isa MB, et al. Measles antibody in pregnant argentinian women relative to vaccine-induced immunity and natural infection. Pediatr Infect Dis J 1999; 18:937-9.
15. Papania M, Baughman AL, Lee S, et al. Increased susceptibility to measles in infants in the United States. Pediatrics 1999;104:59.
16. Peltola H, Heinonen OP, Vaslle M, et al. The elimination of indigenous measles, mumps, and rubella from Finland by a 12- year, two-dose vaccination program. N Engl J Med 1994;331:1397-402.
17. Zotti C, Cortese MG, Dall’Acqua M, et al. Vaccinazione antimorbillo: reattogenicità e immunogenicità di vaccini di ceppo Schwarz e di ceppo Edmonston-Zagreb. Soc Ital Med Prevent San Pubbl, 36° Congresso nazionale, Sassari 28 settembre-1 ottobre 1994.
2. Bennett JV, Cutts FT, Katz SL. Edmonston- Zagreb measles vaccine: a good vaccine with an image problem. Pediatrics 1999;04: 1123.
3. Centers for Disease Control and Prevention Measles eradication: recommendation from Meeting cosponsored by the World Health Organization, the Pan American Health Organization, and CDC. MMWR 1997; 46:No RR-11.
4. Centers for Disease Control and Prevention, Measles, United States, 1997. MMWR 1998;47:273-6.
5. Centers for Disease Control and Prevention. Epidemiology of measles, United States
1998. MMWR 1999;48:749-53.
6. Conferenza permanente per i rapporti tra lo Stato, le Regioni e le Province autonome di Trento e di Bolzano – Piano Nazionale Vaccini 1999-2000. Gazzetta Ufficiale n. 176 del 29 luglio 1999, serie generale.
7. De Serres G, Joly JR, Fauvel M, et al. Passive immunity against measles during the first 8 months of life of infant born to vaccinated mothers or to mothers who sustained measles. Vaccine 1997;15:620-3.
8. Gans HA, Arvin AM, Galinus J. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA 1998;280:527-32.
9. German B, Sirota L, Barzilai A, et al. Placental transfer of maternal measles antibodies to pre-term and full-term infants. American Pediatric Society for Pediatric Research, 1-5 maggio 1998, New Orleans (839 abstract).
10. Grilli G, Cimini D, Vacca F, et al. Effetti collaterali e sieroconversione dopo la vaccinazione contro il morbillo, effettuata con ceppi vaccinali Edmonston-Zagreb e Schwarz. Notiz Ist Sup Sanità 1994;7:1-8.
11. Gruppo di lavoro ICONA - ICONA: indagine nazionale sulla copertura vaccinale infantile. Rapporti ISTISAN, ISS 98/33.
12. James JM, Burks AW, Roberson PK, Sampson HA. Safe administration of the measles vaccine to children allergic to eggs. N Engl J Med 1995;332:1262-6.
13. Markowitz L, Sepulveda J, Diaz-Ortega JL. Immunization of six-months-old infants with different doses of Edmonston-Zagreb vaccine at age 6 months. N Engl J Med 1990;322:580-7.
14. Nates SV, Cumino A, Isa MB, et al. Measles antibody in pregnant argentinian women relative to vaccine-induced immunity and natural infection. Pediatr Infect Dis J 1999; 18:937-9.
15. Papania M, Baughman AL, Lee S, et al. Increased susceptibility to measles in infants in the United States. Pediatrics 1999;104:59.
16. Peltola H, Heinonen OP, Vaslle M, et al. The elimination of indigenous measles, mumps, and rubella from Finland by a 12- year, two-dose vaccination program. N Engl J Med 1994;331:1397-402.
17. Zotti C, Cortese MG, Dall’Acqua M, et al. Vaccinazione antimorbillo: reattogenicità e immunogenicità di vaccini di ceppo Schwarz e di ceppo Edmonston-Zagreb. Soc Ital Med Prevent San Pubbl, 36° Congresso nazionale, Sassari 28 settembre-1 ottobre 1994.